The Latest Analyst Ratings for Legend Biotech
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish ratings for Legend Biotech (NASDAQ:LEGN) in the last quarter. In the last 3 months, 11 analysts have offered 12-month price targets for Legend Biotech, with an average price target of $84.91, an increase of 10.47% from the previous average price target of $76.86.
August 16, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bullish analyst ratings and an increased price target suggest a positive outlook for Legend Biotech.
Analysts have provided bullish ratings for Legend Biotech and increased the average price target by 10.47%. This suggests a positive outlook for the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100